Genmab Net Income 2010-2024 | GNMSF

Genmab net income for the twelve months ending December 31, 2024 was $1.137B, a 79.99% increase year-over-year.

  • Genmab annual net income for 2024 was $1.137B, a 79.99% increase from 2023.
  • Genmab annual net income for 2023 was $0.632B, a 19.18% decline from 2022.
  • Genmab annual net income for 2022 was $0.782B, a 63.38% increase from 2021.

Genmab Net Income 2010-2024 | GNMSF

  • Genmab annual net income for 2024 was $1.137B, a 79.99% increase from 2023.
  • Genmab annual net income for 2023 was $0.632B, a 19.18% decline from 2022.
  • Genmab annual net income for 2022 was $0.782B, a 63.38% increase from 2021.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$160.1B
Vertex Pharmaceuticals (VRTX)$123.9B
Gilead Sciences (GILD)$122.2B
Bristol Myers Squibb (BMY)$116.5B
CSL (CSLLY)$82.8B
Regeneron Pharmaceuticals (REGN)$79.3B
GSK (GSK)$75.4B
Argenex SE (ARGX)$40B
Alnylam Pharmaceuticals (ALNY)$35.9B
BioNTech SE (BNTX)$28.8B
BeiGene (ONC)$22.4B
Biogen (BIIB)$20.7B
Illumina (ILMN)$19.5B
Insmed (INSM)$14.5B
Incyte (INCY)$14.4B
Intra-Cellular Therapies (ITCI)$13.5B
Moderna (MRNA)$12.9B
Genmab (GMAB)$12.8B
BioMarin Pharmaceutical (BMRN)$12.3B
Bio-Techne Corp (TECH)$11.9B
Vaxcyte (PCVX)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Sarepta Therapeutics (SRPT)$10.7B
Exact Sciences (EXAS)$10B
Bio-Rad Laboratories (BIO.B)$9.6B
Exelixis (EXEL)$9.6B
QIAGEN (QGEN)$9.4B
Repligen (RGEN)$9.1B
Roivant Sciences (ROIV)$7.9B
Ascendis Pharma (ASND)$7.6B